Response Biomedical Corp. Announces Execution of New

Response Biomedical Corp. Announces Execution of New Distribution
Agreement with Fisher HealthCare for U.S. Distribution of its
Response Infectious Disease Products 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/24/13 -- Response
Biomedical Corp. (TSX:RBM)(OTCBB:RPBIF) (Response) announced today
that it has entered into a new nonexclusive distribution agreement
with Fisher HealthCare, part of Thermo Fisher Scientific to
distribute its Infectious Disease portfolio of RAMP(R) products in
the U.S. Fisher HealthCare is a global distributor of innovative
diagnostic technologies and laboratory products to hospitals,
physician office laboratories and alternate healthcare settings.  
This is the second agreement entered into between Response's newly
formed, wholly owned U.S. subsidiary, Response Point of Care Inc.,
and a U.S. distributor in January 2013. Fisher will market Response's
Infectious Disease Point of Care (POC) test panel, which currently
includes the RAMP(R) Flu A + B test and the RAMP(R) RSV test, on the
RAMP(R) 200.  
"This is a key strategic agreement for Response as we continue our
investment into the U.S. marketplace for POC testing. The knowledge
and experience of Fisher HealthCare in this market is a vital part of
our strategy to substantially increase our penetration into this
highly competitive region. Our recent activity and focus within the
U.S. market has set an excellent foundation for growth highlighted by
these significant partnerships with well established and well
respected companies," stated Tim Shannon, Senior Vice President of
Worldwide Sales and Marketing for Response Biomedical Corp. "As
widely reported in the media, this year's influenza season is severe
which makes this agreement timely," added Shannon. 
Response's Flu A + B and RSV tests are run on the RAMP(R) 200 Reader
(the "Reader") diagnostic platform that quickly delivers objective
results through an easy-to-use self-timed Reader. The Reader detects
positive or negative results within 15 minutes that are directly
correlated with the presence or absence of the Flu A and B
nucleoprotein antigens or RSV F-protein antigen. For the Flu A + B
test, the Reader differentiates between and detects both influenza A
and B antigens and the result is displayed by the automated Reader.
Th
e fluorescence-reading Reader helps eliminate user interpretation
errors, which can lead to both false negative or false positive
results. Additionally, the Reader stores test results which gives lab
technicians more flexibility in time and test management. The
Reader's ability to export data further reduces the potential for
reporting errors by eliminating the need for manual transfer of
patient results. Rapid detection of RSV and/or Flu A + B aids
hospital laboratories and physician office laboratories in the rapid
diagnosis and treatment of patients. The RAMP(R) 200 Reader has
innovative design features, including multi-port capability to run up
to 12 tests per hour on one module and up to 36 tests per hour, using
three modules. This allows tests to be run on multiple patients
simultaneously or multiple assays to be run for one patient. More
information on the proprietary RAMP(R) Platform can be found at
www.responsebio.com 
The Market 
Seasonal influenza is a highly variable, contagious and potentially
life-threatening viral respiratory infection. Influenza can lead to
severe complications and results in approximately 3,000 - 49,000
seasonal influenza-related deaths in the United States every year.(i) 
RSV in the United States is responsible for thousands of annual
hospitalizations among children younger than one year. It is believed
to be the most common viral cause of death in children younger than
five years and in particular, in children younger than one year. In
the first two years of life, virtually all children are infected with
the virus at some point.(ii) 
About Response Biomedical Corp. 
Response develops, manufactures and markets rapid on-site diagnostic
tests for use with its RAMP(R) platform for clinical and
environmental applications. RAMP(R) represents a unique paradigm in
diagnostics that provides reliable laboratory quality results in
minutes. It is ideally suited to both point of care testing and
laboratory use. 
The RAMP(R) Platform consists of a reader and single-use disposable
test cartridges, and has the potential to be adapted to more than 250
medical and non-medical tests currently performed in laboratories.
Response clinical tests are commercially available for the early
detection of heart attack, congestive heart failure, Flu A + B and
RSV. In the non-clinical market, RAMP(R) tests are currently provided
for the environmental detection of West Nile Virus and for Biodefense
applications including the rapid on-site detection of anthrax,
smallpox, ricin and botulinum toxin. 
The Company has achieved 510(k) clearance for RAMP(R) Flu A + B and
RAMP(R) RSV on the RAMP(R) 200 and its Quality Management System is
registered to ISO 13485: 2003 and ISO 9001: 2008.  
Response is a publicly traded company listed on the TSX under the
trading symbol "RBM" and quoted on the OTC Bulletin Board under the
symbol "RPBIF". For further information, please visit the Company's
website at www.responsebio.com.  
Forward-Looking Statements 
This press release may contain forward-looking statements. These
statements relate to future events and are subject to risks,
uncertainties and assumptions about Response Biomedical Corp.
Examples of forward-looking statements in this press release include
statements regarding our penetration into the U.S. POC testing
market, the expansion of the RAMP(R) Platform into U.S. based
hospitals and laboratories and the impact that it will have on the
Company's growth in the near term and beyond. These statements are
only predictions based on the Company's current expectations and
projections about future events. Although the Company believes the
expectations reflected in such forward-looking statements, and the
assumptions upon which such forward-looking statements are made, are
reasonable, there can be no assurance that such expectations will
prove to be correct.  
Readers are cautioned not to place undue reliance on forward-looking
statements included in this news release, as there can be no
assurance that the plans, intentions or expectations upon which the
forward-looking statements are based will occur. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Many factors may cause the Company's actual results to
differ materially from any forward-looking statement, including the
factors detailed in the Company's filings with the Securities and
Exchange Commission and Canadian securities regulatory authorities,
including but not limited to our amended annual report on Form 10-K,
our quarterly reports on Form 10-Q, our Annual Information Form and
other filings with the Securities and Exchange Commission and
Canadian securities regulatory authorities.  
The forward-looking statements contained in this news release are
current as of the date hereof and are qualified in their entirety by
this cautionary statement. Except as expressly required by applicable
securities laws, the Company does not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.  
(i) CDC. http:www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm
(MMWR 2010; 52(33): 1057-1062) 
(ii) CDC. http:www.cdc.gov/RSV
Contacts:
Response Biomedical Corp.
Patricia Massitti
VP, Administration & Corporate Communications
604-456-6010
ir@responsebio.com
www.responsebio.com
 
 
Press spacebar to pause and continue. Press esc to stop.